How big is Masimo Corp.?

As of Jun 18, Masimo Corp. has a market capitalization of $11.27 billion, with recent net sales of $1.97 billion and a net profit of -$276.6 million. Shareholder's funds are $1.05 billion, and total assets amount to $2.63 billion.

Market Cap: As of Jun 18, Masimo Corp. has a market capitalization of 11,273.34 million, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Masimo Corp. reported net sales of 1,973.60 million and a net profit of -276.60 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 1,051.90 million, while total assets were reported at 2,625.70 million.

What does Masimo Corp. do?

Masimo Corporation is a mid-cap medical technology company specializing in non-invasive patient monitoring technologies, with net sales of $372 million and a market cap of approximately $11.27 billion as of March 2025. Key financial metrics include a P/E ratio of 409.00 and a return on equity of 3.14%.

Overview: <BR>Masimo Corporation is a medical technology company that develops, manufactures, and markets a range of non-invasive patient monitoring technologies, operating within the Pharmaceuticals & Biotechnology industry and categorized as a mid-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 372 Million (Quarterly Results - Mar 2025) <BR>Net Profit: 47 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 11,273.34 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 409.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.56 <BR>Return on Equity: 3.14% <BR>Price to Book: 11.91<BR><BR>Contact Details: <BR>Address: 52 Discovery, IRVINE CA : 92618-3105 <BR>Tel: ['1 949 2977000', '1 949 2977077'] <BR>Fax: 1 949 2977499 <BR>Website: https://www.masimo.com/

Should I buy, sell or hold Masimo Corp.?

Who are in the management team of Masimo Corp.?

As of March 2022, the management team of Masimo Corp. is led by Mr. Joseph Kiani, Chairman and CEO, alongside Independent Directors Dr. Steven Barker, Mr. H. Michael Cohen, Mr. Sanford Fitch, Sen. (Retd.) Thomas Harkin, and Mr. Adam Mikkelson.

As of March 2022, the management team of Masimo Corp. includes Mr. Joseph Kiani, who serves as the Chairman of the Board and Chief Executive Officer. Other members of the Board of Directors are Dr. Steven Barker, Mr. H Michael Cohen, Mr. Sanford Fitch, Sen. (Retd.) Thomas Harkin, and Mr. Adam Mikkelson, all of whom hold the designation of Independent Director.

Is Masimo Corp. overvalued or undervalued?

As of February 25, 2025, Masimo Corp. is considered overvalued and risky due to its high P/E ratio of 409 and negative YTD return of -13.49%, significantly underperforming compared to industry peers and the S&P 500.

As of 25 February 2025, the valuation grade for Masimo Corp. has moved from expensive to risky, indicating a shift in perception regarding its market valuation. The company appears to be overvalued given its high P/E ratio of 409, a Price to Book Value of 12.86, and an EV to EBITDA of 73.89. In comparison, peers like QIAGEN NV and Bio-Rad Laboratories, Inc. have much lower P/E ratios of 24.20 and 16.20, respectively, suggesting that Masimo Corp. is priced significantly higher than its industry counterparts.<BR><BR>Recent performance metrics further support the overvaluation narrative, with Masimo Corp. showing negative returns across multiple periods, including a YTD return of -13.49% compared to the S&P 500's 12.22%. This stark contrast highlights the company's struggles in delivering value to shareholders relative to broader market performance.

Is Masimo Corp. technically bullish or bearish?

As of October 10, 2025, Masimo Corp. is in a bearish trend with moderate strength, supported by bearish signals from the MACD, Bollinger Bands, and daily moving averages, while the Dow Theory presents a mixed view and the RSI shows no signals.

As of 10 October 2025, the technical trend for Masimo Corp. has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength indicated by the weekly MACD and Bollinger Bands both showing bearish signals. The daily moving averages also confirm a bearish outlook. The Dow Theory presents a mixed view with a mildly bullish weekly signal but a mildly bearish monthly signal, while the KST is bearish on the weekly and mildly bearish on the monthly. The RSI shows no signals on both time frames. There is no available return data to compare the company's performance against the S&P 500.